TG Therapeutics (NASDAQ:TGTX) Director Sells $274,800.00 in Stock

TG Therapeutics, Inc. (NASDAQ:TGTX) Director Laurence Charney sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $54.96, for a total transaction of $274,800.00. Following the transaction, the director directly owned 168,640 shares of the company’s stock, valued at approximately $9,268,454.40. This trade represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

TG Therapeutics Trading Up 5.3%

Shares of TG Therapeutics stock opened at $55.85 on Thursday. TG Therapeutics, Inc. has a 1 year low of $26.76 and a 1 year high of $59.30. The company has a debt-to-equity ratio of 1.23, a current ratio of 4.27 and a quick ratio of 3.72. The business has a 50 day moving average price of $53.48 and a 200 day moving average price of $44.28. The company has a market capitalization of $8.55 billion, a P/E ratio of 20.38, a P/E/G ratio of 2.27 and a beta of 1.67.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.26). TG Therapeutics had a net margin of 55.22% and a return on equity of 73.49%. The company had revenue of $240.34 million for the quarter, compared to analyst estimates of $229.77 million. During the same quarter last year, the company posted $0.17 EPS. TG Therapeutics’s quarterly revenue was up 70.2% compared to the same quarter last year. Sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.92 EPS for the current fiscal year.

Institutional Investors Weigh In On TG Therapeutics

A number of institutional investors have recently bought and sold shares of TGTX. EverSource Wealth Advisors LLC raised its stake in TG Therapeutics by 51.9% during the first quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 365 shares during the period. Hantz Financial Services Inc. grew its stake in shares of TG Therapeutics by 82.7% during the 4th quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 560 shares during the period. Harbor Investment Advisory LLC acquired a new stake in shares of TG Therapeutics during the 2nd quarter worth $96,000. Covestor Ltd raised its position in shares of TG Therapeutics by 563.0% in the 4th quarter. Covestor Ltd now owns 1,810 shares of the biopharmaceutical company’s stock worth $54,000 after buying an additional 1,537 shares during the period. Finally, Pingora Partners LLC raised its position in shares of TG Therapeutics by 31.2% in the 4th quarter. Pingora Partners LLC now owns 2,100 shares of the biopharmaceutical company’s stock worth $63,000 after buying an additional 500 shares during the period. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently commented on TGTX. Zacks Research downgraded shares of TG Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, September 7th. JPMorgan Chase & Co. raised their price target on shares of TG Therapeutics from $65.00 to $72.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. HC Wainwright reiterated a “buy” rating and set a $78.00 price target on shares of TG Therapeutics in a report on Tuesday, September 1st. Weiss Ratings reissued a “hold (c+)” rating on shares of TG Therapeutics in a research report on Wednesday, July 29th. Finally, B. Riley Financial raised their target price on shares of TG Therapeutics from $55.00 to $86.00 and gave the stock a “buy” rating in a research report on Monday, July 27th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $63.00.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for B-cell diseases and autoimmune disorders. The company’s research and development programs are centered on therapies that target B cells, which play an important role in several immune-mediated conditions.

TG Therapeutics’ principal product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved by the U.S. Food and Drug Administration for the treatment of adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting multiple sclerosis and active secondary progressive multiple sclerosis.